Analytical method development and Validation for simultaneous estimation Of anti cancer anti hiv 1 and anti viral Drugs in formulations and degradation Studies by uplc

Abstract

The objective of the present investigation has been to develop a simple, Accurate, precise newlinemethod for the simultaneous estimation of Anti-cancer,Anti HIV-1 and Anti viral and its newlineapplication to its pharmaceutical dosage forms.1) Encorafenib and binimetinib newlineChromatogram was run through HSS C18 100 x 2.1 mm, 2and#61549;m. Mobile phase containing newline0.01N Kh2po4: Acetonitrile taken in the ratio 70:30 was pumped through column at a flow newlinerate of 0.3 ml/min. Temperature was maintained at 30°C. Optimized wavelength selected was newline248 nm. Retention time of Binimetinib and Encorafenib were found to be 1.182 min and newline1.804. %RSD of the Encorafenib and Binimetinib were and found to be 0.6 and 0.6 newlinerespectively. %Recovery was obtained as 99.72% and 99.77% for Encorafenib and newlineBinimetinib respectively. LOD, LOQ values obtained from regression equations of newlineEncorafenib and Binimetinib were 0.24, 0.74 and 0.03, 0.08 respectively. Regression newlineequation of Encorafenib is y = 26691x + 7831.5 and y = 54983x + 1850.4 of Binimetinib. newlineRetention times were decreased and that run time was decreased. 2) Dolutegravir and newlineTenofovir Chromatogram was run through Hibar100 50x2.1mm, 2and#61549;. Mobile phase newlinecontaining 0.1% OPA and acetonitrile in the ratio of 60:40 v/v was pumped through column newlineat a flow rate of 1.0ml/min. Temperature was maintained at 30°C. Optimized wavelength newlinefor Emtricitabine, Dolutegravir and Tenofovir was 260.0 nm Retention time of Dolutegravir, newlineEmtricitabine and Tenofovir were found to be 1.951 min, 1.180 min and 1.584 min %RSD of newlinesystem precision for Dolutegravir, Emtricitabine and Tenofovir were and found to be 1.0, 0.9 newlineand 0.9 respectively. % RSD of method precision for Dolutegravir, Emtricitabine and newlineTenofovir were and found to be 1.1, 0.7, and 0.4 respectively. % Recovery was obtained as newline100.04%, 99.48% and 99.58% for Dolutegravir, Emtricitabine and Tenofovir respectively. newlineLOD, LOQ values are obtained from regression equations of Emtricitabine, Dolutegravir and newlineTenofovir were 0.47 ppm, 0.11 ppm, 0.06 ppm and 1.44 ppm, 0.34 ppm, 0.18 ppm newlinerespectively. Regression equation of Tenofovir was y = 9033.x + 651.7, Emtricitabine was y newline= 14988x + 10437 and of Dolutegravir was y = 33277x + 12509.Retention times are newlinedecreased. 3) Cabotegravir and Rilpivirine in pharmaceutical dosage form. Chromatogram newlinewas run through Hibar C18 100 x 2.1 mm, 2and#61549;m. Mobile phase containing Water: Acetonitrile newlinetaken in the ratio 55:45 was pumped through column at a flow rate of 0.3 ml/min. newlineTemperature was maintained at 30°C. newline